Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20099911 | 0.88 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL506497 | 0.86 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| Hydrochloric Acid SCHEMBL11095592 | 0.85 | ALDH1A1 (0.53) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL14554001 | 0.83 | PDE10A (0.43) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL26720549 | 0.81 | PDE10A (0.42) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL27553086 | 0.81 | PDE10A (0.42) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL8554211 | 0.81 | PDE10A (0.42) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL17061218 | 0.80 | LMNA (0.53) | L3MBTL1ALDH1A1RAB9AADORA2ALMNA | |
| SCHEMBL2540326 | 0.79 | SMN1; SMN2 (0.44) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB | |
| SCHEMBL8371346 | 0.79 | PLAU (0.44) | L3MBTL1ALDH1A1PLAUPDE10APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| CN-102482264-A | 2-carbamoyl-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| EP-2448934-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | AstraZeneca AB (SE) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 2715/4885ALDH1A1 2943/4885PLAU 4163/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 2705/4885ALDH1A1 2681/4885PLAU 4203/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | L3MBTL1 3074/4885ALDH1A1 1816/4885PLAU 3553/4885 |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | C1R, HTR4, HTR2C | L3MBTL1 2021/4885ALDH1A1 931/4885PLAU 4771/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | L3MBTL1 3390/4885ALDH1A1 1957/4885PLAU 3715/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | L3MBTL1 3454/4885ALDH1A1 2055/4885PLAU 3702/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 2705/4885ALDH1A1 2681/4885PLAU 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.